NasdaqGS:VRTXBiotechs
Vertex Label Expansions Extend CF Reach And Support Cash Engine
Vertex Pharmaceuticals received FDA approval to expand the use of ALYFTREK and TRIKAFTA to additional age groups and CFTR gene variants.
The expanded labels make CFTR modulator treatment options available to an estimated 95% of people with cystic fibrosis in the US.
These decisions materially increase the eligible US patient pool for Vertex's cystic fibrosis franchise.
For investors tracking NasdaqGS:VRTX, the fresh label expansions arrive as the stock trades around $447.26. Shares have...